Special Issue

Novel Antimicrobial Agents: Design, Synthesis and Biological Evaluation

Message from the Guest Editor

Although most bacterial infections can now be effectively controlled with the available arsenal of antibiotics, the emergence of antibiotic resistance (AMR) has led to less effective infection management and higher healthcare costs, longer hospital stays, and higher mortality rates. Over the past 30 years, modern antibacterial drug development has faced an extraordinarily low output of new antibacterial drugs. On the other hand, many new cutting-edge technologies developed in the last two decades have not yet succeeded in improving the performance of clinical pipelines for antibacterial agents. This Special Issue hopes to receive manuscripts that can be broadly classified as addressing the field of the medicinal chemistry of antibacterial compounds. Although we hope to receive manuscripts that describe the design and preparation of new classes of antibacterial agents with novel mechanisms of action, we will also accept manuscripts that describe the chemical synthesis and optimization of existing antibacterial agents, both semisynthetic and fully synthetic.

Guest Editor

Dr. Rok Frlan

The Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia

Deadline for manuscript submissions

closed (31 January 2024)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/139336

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI